Beta Bionics, Inc. filed an 8-K with the U.S. Securities and Exchange Commission on September 15, 2026, disclosing FDA clearance of its Mint patch pump and submission of a 510(k) application for its 3D Intelligence insulin dosing algorithm, both announced on September 14, 2026.

Key Highlights

  • FDA Clearance: The U.S. Food and Drug Administration cleared Mint, the company's patch pump, as announced on September 14, 2026.
  • Commercial Launch Timeline: Beta Bionics expects to initiate the full commercial launch of Mint in the United States in the first quarter of 2027.
  • Manufacturing Capacity: The company anticipates manufacturing capacity to produce at least 1.5 million total disposable units in the full year 2027.
  • Coverage Expectations: Approximately 40% of insured U.S. lives are expected to be able to purchase Mint using their pharmacy benefit at launch, with anticipated coverage increasing to at least 50% within the first year of full commercialization.
  • 3D Intelligence Submission: Beta Bionics submitted a 510(k) application to the FDA for 3D Intelligence, its anticipated next-generation insulin dosing algorithm, on September 14, 2026.
  • iLet Real-World Data: Based on data from 14,952 iLet users with baseline HbA1c data over the period May 19, 2023 to May 18, 2025, greater than 84% met American Diabetes Association hypoglycemia goals.
  • Emerging Growth Company: Beta Bionics is designated as an emerging growth company under applicable SEC rules, as indicated in the filing.

Beta Bionics Details Mint Launch Plans and 3D Intelligence Pipeline

According to the filing, Beta Bionics (NASDAQ:BBNX) announced FDA clearance of Mint, described in the 8-K as "our patch pump featuring a transformative reusable and disposable architecture that does not require recharging." The device integrates with continuous glucose monitors (CGMs) including Dexcom G7, Dexcom G7 15 Day, and Abbott's FreeStyle Libre 3 Plus, and supports both iOS and Android smartphone control. The company disclosed that Mint features a three-day wear time with an additional 12-hour grace period, a 200-unit insulin reservoir, and an IPX8 waterproof rating for up to 5 feet deep for 60 minutes. The filing states the device is expected to launch exclusively through the pharmacy channel.

The filing also reported that on September 14, 2026, Beta Bionics submitted a 510(k) application to the FDA for 3D Intelligence, characterized as "our anticipated next-generation insulin dosing algorithm." According to the disclosure, 3D Intelligence is designed with three algorithm experiences: Original, Optimized, and Conservative. Subject to FDA clearance, the algorithm is expected to power both iLet 3D and Mint 3D platforms. The company disclosed that commercialization of iLet 3D in the United States is expected by the end of 2026, and Mint 3D commercialization is expected simultaneously with the full Mint launch in the first quarter of 2027, in each case subject to regulatory clearance.

The filing included real-world data from iLet users covering the period May 19, 2023 to May 18, 2025. Among 14,952 iLet users with baseline HbA1c data who uploaded data to the company, the filing reported an overall HbA1c of 8.9% to a glucose management indicator (GMI) of 7.3%, described as "an average reduction of 1.5%." The company also disclosed it is developing a fully-closed loop algorithm and intends to initiate a pivotal trial in adults with type 1 and type 2 diabetes "in the coming quarters." The filing notes that all statements regarding future commercialization timelines are the company's own and subject to its cautionary language regarding forward-looking statements.

What Was Disclosed

Beta Bionics filed an 8-K on September 15, 2026 under Items 7.01 and 8.01, disclosing FDA clearance of its Mint patch pump, a 510(k) submission for its 3D Intelligence algorithm, planned commercial launch timing, expected insurance coverage, manufacturing capacity projections, and real-world iLet clinical data.